CD274 and cancer: In the landscape of cancer immunotherapies, therapeutically targeting immune inhibitory checkpoints through the blockade of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein-1 (PD-1), and programmed death ligand-1 (PD-L1) are most broadly effective (2, 3).